Digbi Health, a leader in Precision Biology and personalized healthcare, has been invited to present a groundbreaking study at the Obesity Society Conference. The research highlights how the Digbi Health program effectively modifies the gut microbiome to boost the body’s natural production of endogenous GLP-1 (glucagon-like peptide-1). This innovative approach has the potential to reduce the need for GLP-1 medication dosages, enhance weight loss, improve medication adherence, and lower treatment costs for employers, health plans, and consumers, all while supporting long-term weight loss success.
As GLP-1 medications like Ozempic™, Wegovy™, and Zepbound™ gain popularity for obesity treatment, Digbi Health’s research addresses key challenges associated with these drugs, including gastrointestinal discomfort, adherence, and cost management.
Key Findings from the Study:
Increased Endogenous GLP-1 Production: The study reveals that personalized dietary interventions can effectively modulate the gut microbiome, enhancing the body’s natural GLP-1 production. This reduces the necessity for higher doses of GLP-1 medications, enabling patients to achieve similar weight loss and metabolic benefits with fewer side effects.
Reduction in GI Discomfort: Over 40% of patients using GLP-1 medications report gastrointestinal issues like nausea and bloating. By boosting endogenous GLP-1 levels through the Digbi program, patients can lower their medication dosages, alleviating these symptoms and improving overall comfort.
Lower Dosage, Better Adherence: With increased natural GLP-1 production, patients can often decrease their reliance on external GLP-1 drugs while maintaining effectiveness. This leads to improved adherence to treatment and enhanced success in long-term weight management.
Cost Reduction & Successful Tapering: Utilizing food and gut microbiome interventions allows patients to reduce their medication needs, resulting in lower healthcare costs. Additionally, the ability to taper off GLP-1 medications provides a sustainable and cost-effective approach to achieving health goals.
“This study underscores our commitment to innovative quality and positions Digbi Health at the forefront of the food-as-medicine and gut microbiome revolution. By naturally elevating GLP-1 levels, our approach offers a sustainable alternative or complement to pharmacotherapy, making weight loss treatment more accessible and effective,” stated Ranjan Sinha, CEO of Digbi Health.
“The research we’ve conducted with Digbi Health holds significant promise for understanding the gut microbiome’s role in obesity management,” said Dr. Nova Szoka, MD, Associate Professor of Bariatric Surgery at West Virginia University. “These findings could greatly improve outcomes for patients struggling with weight management by enhancing natural metabolic processes.”
Disclaimer:
Ozempic™, Wegovy™, and Zepbound™ are registered trademarks of their respective manufacturers. The use of these names in this release is for informational purposes only and does not imply endorsement or affiliation with Digbi Health.
About Digbi Health:
Digbi Health is a pioneer in Precision Biology, combining gut microbiome analysis, continuous glucose monitoring (CGM), and genetics to holistically address three of the top four most costly healthcare conditions: obesity, cardiometabolic disorders, and digestive issues. Digbi’s proven approach appeals to employers and health plans seeking to reduce healthcare costs, particularly those associated with GLP-1 medications. The company’s unique dataset and bioinformatics platform integrate millions of data points across genetics, gut microbiome progress, metabolic health, and disease markers, enabling personalized care and optimized treatment strategies.
